Lluís Nisa1,2,3, Urs Borner1, Cilgia Dür1, Andreas Arnold1, Roland Giger4. 1. Department of Otorhinolaryngology, Head and Neck Surgery, Inselspital Bern, University Hospital, University of Bern, 3010, Bern, Switzerland. 2. Department of Radiation Oncology, Inselspital Bern, University Hospital, University of Bern, Bern, Switzerland. 3. Department of Biomedical Research, University of Bern, Bern, Switzerland. 4. Department of Otorhinolaryngology, Head and Neck Surgery, Inselspital Bern, University Hospital, University of Bern, 3010, Bern, Switzerland. roland.giger@insel.ch.
Abstract
OBJECTIVE: Recurrent parotid gland carcinomas (PGCs) are poorly characterized and studies focusing on this topic are rare due to their low incidence. The goal of this study is to analyze the therapeutic strategies, prognostic factors, and oncological outcomes of a series of patients with recurrent PGCs. PATIENTS AND METHODS: Retrospective chart review (1997-2012) of patients with recurrent PGCs was initially treated with curative intent. RESULTS: We identified 20 patients with recurrent PGCs. Eleven patients presented isolated local, regional, or distant metastases, while the rest had recurrences in multiple sites. Recurrent tumors tended to present more advanced T-stage (p = 0.01) and overall stage (p < 0.001), but not N-stage (p = 0.74) when compared to the initial tumors. Half the patients (50%) had distant metastases at the moment of recurrence diagnosis, and another three developed them after attempted salvage surgery. Only 8/20 patients with isolated local or regional recurrences were surgically salvaged with extended revision parotidectomy and neck dissection, respectively. The remaining 12 patients were managed on palliative basis. Overall survival (31.70 months vs. 20.73 months) and progression-free survival (28.70 months vs. 13.61 months) were not significantly different in patients managed surgically vs. palliatively. CONCLUSION: Recurrent PGCs are aggressive neoplasms with a high rate of distant metastases. Surgical salvage can be considered in patients with limited local and/or regional recurrences. The alternative to surgical salvage is palliative management with different chemotherapeutic regimens. Survival does not differ between the two strategies in the present series.
OBJECTIVE: Recurrent parotid gland carcinomas (PGCs) are poorly characterized and studies focusing on this topic are rare due to their low incidence. The goal of this study is to analyze the therapeutic strategies, prognostic factors, and oncological outcomes of a series of patients with recurrent PGCs. PATIENTS AND METHODS: Retrospective chart review (1997-2012) of patients with recurrent PGCs was initially treated with curative intent. RESULTS: We identified 20 patients with recurrent PGCs. Eleven patients presented isolated local, regional, or distant metastases, while the rest had recurrences in multiple sites. Recurrent tumors tended to present more advanced T-stage (p = 0.01) and overall stage (p < 0.001), but not N-stage (p = 0.74) when compared to the initial tumors. Half the patients (50%) had distant metastases at the moment of recurrence diagnosis, and another three developed them after attempted salvage surgery. Only 8/20 patients with isolated local or regional recurrences were surgically salvaged with extended revision parotidectomy and neck dissection, respectively. The remaining 12 patients were managed on palliative basis. Overall survival (31.70 months vs. 20.73 months) and progression-free survival (28.70 months vs. 13.61 months) were not significantly different in patients managed surgically vs. palliatively. CONCLUSION: Recurrent PGCs are aggressive neoplasms with a high rate of distant metastases. Surgical salvage can be considered in patients with limited local and/or regional recurrences. The alternative to surgical salvage is palliative management with different chemotherapeutic regimens. Survival does not differ between the two strategies in the present series.
Entities:
Keywords:
Outcomes; Palliative therapy; Parotid cancer; Recurrence; Salvage surgery
Authors: Aaron W Pederson; Daniel J Haraf; Elizabeth A Blair; Kerstin M Stenson; Mary-Ellyn Witt; Everett E Vokes; Joseph K Salama Journal: Radiother Oncol Date: 2010-04-10 Impact factor: 6.280
Authors: Laura D Locati; Marco Guzzo; Paolo Bossi; Paolo P Brega Massone; Barbara Conti; Elena Fumagalli; Claudia Bareggi; Giulio Cantù; Lisa Licitra Journal: Oral Oncol Date: 2005-10 Impact factor: 5.337
Authors: Roberto A Lima; Marcos R Tavares; Fernando L Dias; Jacob Kligerman; Marilene F Nascimento; Mauro M Barbosa; Claudio R Cernea; Jose R Soares; Izabella C Santos; Scheylla Salviano Journal: Otolaryngol Head Neck Surg Date: 2005-11 Impact factor: 3.497
Authors: Allen M Chen; M Kara Bucci; Jeanne M Quivey; Joaquin Garcia; David W Eisele; Karen K Fu Journal: Int J Radiat Oncol Biol Phys Date: 2006-09-11 Impact factor: 7.038
Authors: Guy Andry; Marc Hamoir; Laura D Locati; Lisa Licitra; Johannes A Langendijk Journal: Expert Rev Anticancer Ther Date: 2012-09 Impact factor: 4.512